Yuvezzi is undergoing regulatory review for drug approval, with Bain Capital advising related companies and John A. Hovanesian serving as medical advisor.

The entities involved

• FDA →
  • The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.Sat 23:10
  • PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.Sat 21:51
• Bain Capital →

  American alternative investment firm specialized in private equity, venture capital and credit products

  • Bain Capital invested in Israeli defense firms, and Gail's opened a new bakery outlet in Brixton.Wed 12:45
  • Willis Re is expanding its international platform in Europe, targeting the German reinsurance market through a joint venture with WTW and Bain Capital.Mon 19:26

Related events

• Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• FDA and Pfizer are seeking regulatory approval for their products.Aug 29
• Both the FDA and the European Medicines Agency govern drug approval processes.Aug 12
• Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Aug 5